The present invention relates to a product for combination therapies useful for the treatment of cancer diseases. In particular, the invention relates to the combination of an anti-PD-Ll antibody and an MCT4 inhibitor of Formula (I). The therapeutic combination may be utilized for the use in treating a subject having a cancer disease that tests positive for PD-L1 and/or MCT4 expression.
本发明涉及一种用于治疗癌症疾病的联合疗法产品。具体而言,该发明涉及一种抗PD-L1
抗体和一种Formula(I)的
MCT4
抑制剂的组合。该治疗组合可用于治疗对PD-L1和/或
MCT4表达呈阳性的癌症患者。